Q3 2024 Immunovia AB (publ) Earnings Call Transcript
Key Points
- Immunovia AB (LTS:0G8X) achieved significant progress with their next-generation test, showing 85% sensitivity and 98% specificity in detecting pancreatic cancer.
- The company successfully reduced operating expenses by 20% compared to the same quarter last year, primarily due to a 60% reduction in headcount costs.
- Immunovia AB (LTS:0G8X) raised SEK52 million through a rights issue, exceeding expectations with a 91% subscription level.
- The company has acquired over 1,000 blood samples for their clinical validation study, marking it as potentially the largest study of its kind in pancreatic cancer.
- Immunovia AB (LTS:0G8X) plans to launch their test in the US market in the second half of 2025, targeting high-risk pancreatic cancer surveillance centers.
- Cash burn is expected to increase in Q4 due to ongoing R&D activities, projected to be between SEK8 million to SEK10 million.
- Revenue from the test is expected to be limited in 2025, with significant revenue anticipated only after reimbursement approval in 2026.
- The company faces challenges in securing a strategic partner, as potential partners are waiting for clinical validation data before proceeding.
- There is a risk that the clinical validation study may yield different results from the model-development study, which could impact future plans.
- The need for additional clinical studies post-validation could delay broader market adoption and reimbursement processes.
Ladies and gentlemen, welcome to the Immunovia Q3 interim report 2024 conference call. I am Yusuf, the Chorus Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Karin Almqvist Liwendahl, CFO. Please go ahead.
()-
Thank you very much. And with that, I would like to say good morning and a good afternoon, and a warm welcome to all of you joining today to Immunovia's conference call following our third quarter results for 2024.
Presenting in the call today is our CEO, Jeff Borcherding; and myself, Karin Almqvist, CFO of the company. As usual, the presentation will be followed by a Q&A session, which will be guided by our operator. You are welcome to give your questions in the call or post them via the chat function.
After we have closed today's call, you will find the presentation and a recording
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
